We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid

By LabMedica International staff writers
Posted on 03 Nov 2026

Neurological and neuropsychiatric disorders such as Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS) are often diagnosed only after symptoms emerge. More...

By that stage, underlying disease processes in the brain and nervous system may already be advanced. Because brain biopsy is limited by accessibility, there is growing interest in biomarkers that can be measured in biofluids. Building on this approach, researchers now report a framework for isolating neuron-specific extracellular vesicles from blood and cerebrospinal fluid.

The Wyss Institute at Harvard University developed the approach in collaboration with Brigham and Women’s Hospital, the Broad Institute of MIT and Harvard, and Harvard Medical School. The work focuses on extracellular vesicles, membrane-enclosed particles released by cells into biofluids that carry RNA transcripts and proteins. Because neuron-specific extracellular vesicles make up only a very small fraction of vesicles in plasma and other biofluids, the researchers developed methods to identify surface markers that could enable antibody-based isolation.

The team first established a method for isolating the full spectrum of extracellular vesicles from plasma and other body fluids at high purity. The technique uses porous beads that trap and remove free proteins such as albumin while excluding larger extracellular vesicles. According to the researchers, this one-step procedure increased extracellular vesicle purity by an additional 100-fold.

Using mass spectrometry, the researchers then generated reference proteomes for extracellular vesicles from plasma and cerebrospinal fluid. They combined these data with computational analysis of single-cell RNA sequencing studies to prioritize predicted transmembrane proteins whose genes were selectively expressed in neurons. One candidate marker, NRXN3, was confirmed on extracellular vesicles from both plasma and cerebrospinal fluid using ultrasensitive SIMOA detection assays and single-vesicle imaging methods.

The proof-of-concept study was published in Nature Neuroscience on October 23, 2026. The team also developed and validated an immuno-isolation method that reliably isolated NRXN3-carrying extracellular vesicles from human cerebrospinal fluid and plasma samples. The findings provide a framework for further analysis of proteins contained within neuron-derived extracellular vesicles and for identifying additional extracellular vesicle markers associated with other cell types and tissues.

“This project is a significant step towards our goal of reading out the brains of patients through the contents of neuron-specific EVs. We are now measuring specific proteins inside of these EVs to confirm their neuronal origin. Our goal is to look inside neuron-derived EVs for markers that are correlated with earlier stages and the progression of neurological disorders, as well as therapeutic efficacy of present and future drug candidates. More fundamentally, such markers can also help us better understand some of the underlying early pathologies, which for many neurological disorders are not clear at all,” said David Walt, Core Faculty member at the Wyss Institute.

Related Links
Wyss Institute at Harvard University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Elevated creatinine levels do not necessarily indicate impaired kidney function: pre-treatment cystatin C measurement is key to assessment (Image Credit: Data panels adapted from Watanabe H, et al. Clin Pharmacol Ther (2026). All icons were obtained from bioicons.com and modified.)

Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury

Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.